Researchers at the Cincinnati Children’s Hospital Medical Center are testing an injectable allergy suppressor that may work long term. The injection is being tested in mice and will likely see human trials in three to five years.

Lead by University of Cincinnati professor Fred Finkelman, MD, and with funding from Food Allergy Research and Education (FARE), the program combines things already well-known but not correlated.

“There is nothing new under the sun, and what we did was put together two ideas that have been out there for a long time, but maybe put them together in a way that increases their potential as human therapy,” said Finkelman in a release.

The injection is an antibody that removes the IgE molecule that is responsible for allergic reactions. Allergens attach themselves to IgE antibodies, which are distributed throughout the body via the histamine-filled mast cells they sit upon. When an allergen attaches to the IgE antibody, the histamine cells break apart, sending histamines into the body to create reactions.

The idea here is to simply destroy the IgE and their receptors and, at the same time, use “rapid desensitization” to allow a patient’s body to accept the allergen. The goal is to have most allergic reaction gone within 12 to 24 hours of the injection. Finkelman and his team believe that with the help of the injection’s antibodies, they can suppress the allergic reaction enough to allow doctors to give doses of allergens until the body accepts them without reaction, building a sort of immunity in a very short time span.

For now, the team is experimenting with peanut allergies, but they believe the injection covers nearly all allergies as it was developed as a “blanket” rather than being specific.

Trails with mice are continuing, but is on track for human trials in three to five years, the team says.

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}